New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Akari Therapeutics Plc

Contributing Author

Recent Articles by Akari Therapeutics Plc

Sep-24	Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 AKTX GlobeNewswire
Sep-17	Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer AKTX GlobeNewswire
Sep-05	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference AKTX GlobeNewswire
Sep-03	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series AKTX GlobeNewswire
Aug-14	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AKTX GlobeNewswire
Jul-29	Akari Therapeutics Releases Virtual Investor "What This Means" Segment AKTX GlobeNewswire
Jul-23	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers AKTX GlobeNewswire
Jul-22	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference AKTX GlobeNewswire
Jun-25	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent AKTX GlobeNewswire
Jun-18	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India AKTX GlobeNewswire
May-29	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology AKTX GlobeNewswire
May-22	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar AKTX GlobeNewswire
May-15	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update AKTX GlobeNewswire
May-01	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology AKTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.